EMA — authorised 5 January 2024
- Application: EMEA/H/C/006013
- Marketing authorisation holder: Bristol-Myers Squibb Pharma EEIG
- Local brand name: Krazati
- Indication: Krazati as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy.
- Pathway: conditional
- Status: approved
On 5 January 2024, the European Medicines Agency (EMA) granted a conditional marketing authorisation for Krazati (MRTX849), a treatment for adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation. This authorisation was granted under the conditional approval pathway. Krazati is indicated for patients with disease progression after at least one prior systemic therapy.